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Abstract: Several influenza pandemics have occurred in the past century, one of which emerged in
1957 from a zoonotic transmission of H2N2 from an avian reservoir into humans. This pandemic
caused 2–4 million deaths and circulated until 1968. Since the disappearance of H2N2 from human
populations, there has been waning immunity against H2, and this subtype is not currently incorporated into seasonal vaccines. However, H2 influenza remains a pandemic threat due to consistent
circulation in avian reservoirs. Here, we describe a method of pandemic preparedness by creating
an adenoviral-vectored centralized consensus vaccine design against human H2 influenza. We also
assessed the utility of serotype-switching to enhance the protective immune responses seen with
homologous prime-boosting strategies. Immunization with an H2 centralized consensus showed a
wide breadth of antibody responses after vaccination, protection against challenge with a divergent
human H2 strain, and significantly reduced viral load in the lungs after challenge. Further, serotype
switching between two species C adenoviruses enhanced protective antibody titers after heterologous
boosting. These data support the notion that an adenoviral-vectored H2 centralized consensus vaccine has the ability to provide broadly cross-reactive immune responses to protect against divergent
strains of H2 influenza and prepare for a possible pandemic.
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In 1957 the H2N2 “Asian flu” pandemic quickly swept the globe, causing an estimated
2 million deaths in the first year alone [1]. This pandemic strain resulted from a zoonotic
transmission event from a reassorted H2N2 avian and H1N1 human influenza A virus [2].
H2N2 then circulated in human populations until 1968, when the virus was reassorted
again with H3 influenza and resulted in the “Hong Kong” flu. Serological analysis indicates
that people under 50 years old have little-to-no immunity to H2N2 [3] and that seasonal
influenza vaccination does not provide cross-protection [4]. Importantly, H2 influenza is
still consistently isolated from waterfowl, wild birds, and domestic ducks [5–7] and exhibits
substantial pandemic potential. In 2005, the World Health Organization (WHO) set forth a
call to action to create and stockpile vaccines against influenza subtypes with pandemic
potential [8,9]. However, the mutability and reassortment tendencies of influenza viruses
make predicting and protecting against pre-pandemic strains of influenza challenging [10].
It is imperative that efforts be allocated toward creating a broadly protective vaccine
against potential pandemic viruses, including H2 influenza. Recent work characterized
the utility of multivalent inactivated virus vaccines (IIV) against H2 [11], a cold-adapted
live attenuated influenza virus (LAIV) H2 vaccine [12–15], and computationally derived
consensus vaccines against influenza viruses exhibiting pandemic potential [16–20]. Lenny
et al. observed that immunizing with non-human H2 isolates in an IIV platform resulted
in moderate antibody responses; however, these responses were low compared to a LAIV
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H2 vaccine [12]. Nasal administration of the LAIV H2 vaccine was demonstrated to have
high immunogenicity in mice and ferrets [14] and has historically been shown to elicit longlasting systemic cellular immune responses and enhanced levels of secretory IgA at mucosal
surfaces [21]. However, clinical translation of the H2N2 LAIV vaccine to humans has
remained a challenge [15], and consistency between clinical trials suggested that achieving
broad heterologous protection may require a multivalent formulation [12,14]. Further,
this vaccine modality has the potential to mutate [22] and reassort with circulating strains
during co-infection [23,24]. Although reassortment between LAIV and circulating strains
has not yet been described in humans, this was recently observed in swine populations after
vaccination with the nonstructural protein 1 (NS1)-truncated commercial LAIV vaccine [25].
The epidemiological repercussions of this reassortment event have yet to be elucidated, but
this highlights the necessary precautions that need to be considered when administering
LAIV vaccines. Importantly, the AA ca virus, initially created and characterized in the
late 1960s [26,27], has been used as the backbone of seasonal LAIV administered in the
United States. The attenuation and utility of AA ca has been an invaluable contribution
to increasing our understanding of immunological responses to LAIV vaccines and is still
used as the master donor virus (MDV) of many LAIV vaccines today, highlighting its
importance in vaccine development.
The inherent immunogenicity and enhanced stimulation of innate and adaptive immune responses make adenoviral-vectored vaccines an attractive platform to deliver antigens in vivo [28]. Unsurprisingly, adenoviruses (Ads) are the leading vectors applied in
gene therapy clinical trials to treat cancer, cardiovascular diseases, and various infectious
diseases [29]. The utility of Ad as a viral vector against measles, hepatitis B and C, rabies, Ebola, anthrax, human immunodeficiency virus-1 (HIV-1), malaria, and influenza
was previously described [30], and currently, all viral-vectored vaccines approved for use
against the ongoing SARS-CoV-2 pandemic are based on Ad vectors [31–35]. Ad has a
stable, non-integrative double-stranded DNA genome with a large packaging capacity that
can be easily manipulated to be rendered replication-incompetent, exhibiting an enhanced
safety profile in comparison to LAIV. Further, the manufacturing of Ad can be easily scaled
up to mass-produce large quantities of vaccines in the event of a pandemic outbreak [36].
Finally, Ads are grown entirely in cell culture, mitigating the induction of egg-related
allergy responses seen with seasonal influenza virus vaccines [28]. For these reasons, we
utilized a replication-defective Ad vector to deliver our vaccine immunogen.
In order to address the concern of limited cross-protection after immunization with
a wildtype influenza sequence, we utilized a centralized consensus hemagglutinin (HA)
design to offer enhanced cross-reactive immune responses. The HA is the most abundant
glycoprotein on the surface of influenza and is a central target of neutralizing antibodies
during immune responses against vaccination and infection. Our centralized consensus
approach uses representative wildtype HA sequences from each major branch to create a
final consensus construct that localizes to the central node of the phylogenetic tree. These
synthetic constructs minimize the genetic and antigenic differences seen in influenza HA
and remove sampling and reporting biases that naturally occur with global influenza
surveillance programs. We previously showed our centralized consensus approach to
effectively enhance protection against H1, H3, and H5 influenza A viruses and found
that these synthetic immunogens outperformed wildtype strains [16,17]. Further, immunization with a centralized consensus construct of the envelope (env) protein of HIV-1
demonstrated higher efficacy against a wide breadth of divergent strains compared to
wildtype isolates [37–39]. Because of this previous success, we applied this strategy to
create a broadly protective consensus H2 (H2-Con) influenza vaccine.
Here, we describe a method of pandemic preparedness by creating an adenoviralvectored centralized consensus hemagglutinin construct against previously circulating
pandemic strains of human H2 influenza A virus. We found that H2-Con had the ability to
induce broadly protective antibody titers when delivered first by Ad6 and boosted with
Ad5. Further, we observed complete protection against challenges with a divergent H2
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strain in vivo and an enhanced capacity to clear the virus from the lungs. Based on our
results, we showed that an Ad-vectored vaccine strategy could be used to prepare for an
impending pandemic and warrants further investigation into clinical applications.
2. Materials and Methods
2.1. Ethics Statement
All protocols were reviewed and approved by the Institutional Biosafety Committee
(IBC) at the University of Nebraska–Lincoln, as specified in the IBC protocol 1908. Sixto eight-week-old female BALB/c mice were purchased from Jackson Laboratory (Bar
Harbor, ME, USA) and housed at the Life Sciences Annex building on the University of
Nebraska–Lincoln (UNL) campus under the Association for Assessment and Accreditation
of Laboratory Animal Care International (AAALAC) guidelines. All procedures involving
infectious human H2 influenza were completed in the Nebraska Veterinary Diagnostic
Laboratory (NVDL) BSL-3/ABSL-3 facility at UNL. The protocols were approved by the
UNL Institutional Animal Care and Use Committee (IACUC) (Project ID 1908). All animal
experiments were carried out according to the provisions of the Animal Welfare Act, PHS
Animal Welfare Policy, the principles of the NIH Guide for the Care and Use of Laboratory
Animals, and the policies and procedures of UNL. All immunization, bleeds, and infections
were completed under either isoflurane or ketamine/xylazine-induced anesthesia. After the
lethal influenza challenge, mice that reached 25% weight loss were humanely euthanized.
2.2. Influenza Viruses
The following reagents were obtained through BEI Resources, NIAID, NIH: A/Singapore/
1/1957 (Singapore/57) [NR-31132], A/Japan/305/1957 (Japan/57) [NR-347], A/Formosa/313/
1957 (Formosa/57) [NR-15561], A/Korea/426/1968 (HA, NA) × A/Puerto Rico/8/1934
(Korea/68) [NR-3527], A/Rockefeller Institute/5/1957 (RI/57) [NR-3525], A/Japan/305/1957
(Japan/57) [NR-3171], and A/Taiwan/1/1964 (Taiwan/64) [NR-3173]. All viruses were grown
in specific pathogen-free (SPF) eggs, and the allantoic fluid was stored at −80 ◦ C. Grown
viruses were quantified by standard hemagglutination assay (HAU).
2.3. Design of Centralized Consensus Hemagglutinin and Phylogenetic Analysis
All unique, full-length human H2 hemagglutinin (HA) sequences were downloaded
from the Genbank as of 15 June 2007. The resulting 98 sequences were aligned with
ClustalW and used to create a phylogenetic tree. Sixteen H2 HA sequences were chosen to
represent the major branches of the phylogenetic tree and used to create a synthetic centralized consensus protein sequence (accessions: AY209979, AY209957, CY125854, CY014976,
AY209954, L11134, L20409, L11142, AY209959, AY209963, AY209961, AY209962, L11133,
L11125, L11126, and D13579). An alignment of the 16 representative sequences and H2-Con
is shown in Supplemental Figure S1. Briefly, the 16 sequences were aligned using ClustalW,
and the most common amino acid at each position was determined and incorporated into
the synthetic protein sequence. This sequence was then realigned to all unique human H2
strains, and a Neighbor-joining phylogenetic tree was constructed to visualize the designed
centralized consensus protein using Geneious 11.1.5 software and a Jukes–Cantor model
with a Blosum62 cost matrix.
2.4. Construction of Recombinant Adenoviruses
The H2 centralized consensus was codon-optimized for mammalian expression and
synthesized by Genscript, Inc. This consensus H2 construct was previously described
and published by Lingel A. et al. [17]. In this study, we included a more detailed and
comprehensive characterization of the H2-con immunogen. The consensus construct was
cloned into first-generation replication-defective Ad5 (E1/E3 deleted) or Ad6 (E1 deleted)
vectors, as previously described [40]. Recombinant Ad5 and Ad6 carrying the H2-Con gene
were linearized by PacI (New England Biolabs) and transfected into human embryonic
kidney 293 cells (HEK293) using PolyFect Transfection Reagent (Qiagen). The rescued
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constructs were observed for cytopathic effects (CPE) and then amplified in the human
embryonic kidney (HEK) 293 cells by sequential passaging until a final infection of a 10-cell
stack cell factory (Corning). Ad5-H2-Con and Ad6-H2-Con were purified by two steps
of cesium chloride ultracentrifugation, then desalted using Econo-Pac 10DG Desalting
Columns (Bio-Rad). Final vector preparations were quantified by OD260, and infectious
units were confirmed to be equal using the AdenoX Rapid Titer kit according to standard
manufacturer’s instructions (Clontech Laboratories, Mountain View, CA, USA).
2.5. Western Blot
Protein expression of the Ad5 and Ad6 constructs were confirmed with Western blot
analysis. Confluent HEK293 cells were infected at an MOI of 500, incubated for 48 h at
37 ◦ C, 5% CO2 , then harvested. Cells were washed one time with 50 µL of DPBS, then
denatured in 2X Laemmli and 2-mercaptoethanol buffer and heated at 100 ◦ C for 10 min.
Samples were passed through a Qiashredder (Qiagen) and run on 12.5% SDS-PAGE. Protein
was transferred to a nitrocellulose membrane, blocked in 5% milk in 1X TBST for 1 h, then
probed at 4 ◦ C overnight with g-α-A/Singapore/1/1957 (NR-3150) at 1:1000 dilution or
m-α-GAPDH-HRP (sc-47724) at a 1:500 dilution in 1% milk-1X TBST. The membrane was
washed twice with 1X TBST and then probed with a 1:2000 dilution of secondary donkey
α-goat-HRP antibody in 1% milk-1X TBST for 1 h. The final membrane was washed twice
with 1X TBST and developed with SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientific, Waltham, MA, USA).
2.6. Vaccination
Groups of female BALB/c mice (n = 5) were immunized via intramuscular injection
of 1010 vp of either Ad5- or Ad6-H2-Con diluted in 50 uL of DPBS. Two 25 µL doses were
delivered to each hind leg for immunization. Three weeks post-prime, mice were bled
via submandibular puncture and boosted with homologous or heterologous adenoviralvectored (Ad5/Ad6)-H2-Con vaccine. Two weeks later, the mice were bled via cardiac
puncture under ketamine and xylazine-induced anesthesia. Serum was separated from
whole blood using a BD Microtainer Blood Collection Tube (Becton Dickinson) and centrifuged at 6800× g for 2 min, then used in subsequent analysis.
2.7. Hemagglutination Inhibition (HI) Assay
Sera from vaccinated mice were treated at 37 ◦ C overnight with receptor destroying
enzyme (RDE; Denka Seiken) in a 1:3 ratio (sera: RDE), then heat-inactivated at 56 ◦ C for
30 min. Sera were diluted to a final concentration of 1:10 in DPBS, and 25 µL of sera was
serially diluted two-fold down a 96-well v-bottom plate. V-bottom plates were used to
be able to visualize red blood cell pellets during development. An amount of 25 µL of
four hemagglutinating units (4HAU) was added to all wells, and plates were incubated
at room temperature for 1 h before adding 50 µL of 0.5% chicken red blood cells (cRBCs).
Agglutination patterns were read after 30 min of incubation at room temperature.
2.8. Lethal Influenza Challenge, Tissue Collection, and Lung Viral Titers
Groups of female BALB/c mice (n = 10) were primed with 1010 viral particles (vp) of
Ad5-H2-Con, Ad6-H2-Con, or DPBS, then boosted three weeks later with a homologous or
heterologous vaccine. Two weeks after boosting, all mice were challenged with 20 times
the median lethal dose (20MLD50 ) of A/Korea/426/1968 and humanely euthanized at
≥25% baseline weight loss. This virus was chosen from a preliminary lethality study
(supplemental Figure S2) and was already pathogenic in mice without the need for mouse
adaptation. At three days post-infection (3 dpi), half of the mice (n = 5 mice/group)
were sacrificed, and lungs were collected for analysis of lung viral titers by qPCR. Lungs
were homogenized in DPBS, centrifuged at max speed for 10 min, then 100 µL of the
supernatant was subjected to Purelink viral RNA/DNA extraction (Invitrogen) according
to manufacturer’s instructions. Real time-qPCR was performed using the Luna Universal
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One-Step RT-qPCR Kit (NEB) and the Universal influenza A primer set (BEI Resources,
NR-15579 and NR-15580) with the following cycling parameters: 55 ◦ C for 10 min, 95 ◦ C for
2 min, and 45 cycles of 95 ◦ C for 15 secs and 60 ◦ C for 1 min. Final viral RNA concentrations
were determined based on a standard curve from a known quantity of A/Puerto Rico/8/34
viral RNA.
2.9. Statistical Analysis
All data were analyzed using GraphPad Prism software. Data are expressed as the
mean with standard error (SEM). One-way ANOVA statistical analyses were used to
compare groups in HI titers and lung viral titers. A p-value of <0.05 was considered
statistically significant (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).
3. Results
3.1. Construction and Characterization of Centralized Consensus H2 Vaccine Immunogen
The current vaccination strategies incorporate inactivated wildtype strains into clinical
vaccines. In 1957 this was the tactic used to immunize against circulating H2N2 influenzas.
However, this method induced strain-specific responses and provided limited protection
as the pandemic progressed over a ten-year period [2,10]. In order to evaluate the ability
to enhance cross-protection, we generated a centralized consensus hemagglutinin protein
based on antigenically representative human H2 influenza A viruses from 1957 to 1968. This
approach produces a vaccine immunogen that is equidistant to all other divergent strains
and has lower sequence divergence than any given wildtype strain. Further, this technique
removes sampling bias if testing locations have more thorough surveillance and sequencing
methods compared to other locations. As expected, phylogenetic analysis revealed that this
synthetic immunogen localized to the central node of the human H2 influenza A virus tree
(Figure 1A). H2-Con was then cloned into a replication-defective human adenovirus type 5
or human adenovirus type 6 viral vector, and hereafter are referred to as Ad5-H2-Con or
Ad6-H2-Con. The protein expression of the synthetic H2 immunogen from each adenovirus
was confirmed by Western blot (Figure 1B), and antigenic relatedness to strains used in the
study was determined (Figure 1C). The strains used in this study were determined based on
reagent availability and sequence divergence from the H2-Con immunogen. We included
these sequences in determining if H2-Con could induce protective responses against highly
divergent strains that were circulating in both the 1950s and the 1960s.
3.2. Adenoviral-Vectored Consensus H2 Immunogen Induces Protective Humoral
Immune Responses
We first evaluated humoral immune responses after a single vaccination with either
Ad5-H2-Con or Ad6-H2-Con and compared the responses to a PBS sham negative control
group. The breadth of antibody responses was assessed using six different human H2
influenza A viruses selected from 1957 to 1968 and assayed by hemagglutination inhibition
(HI) titer. HI titers ≥ 40 are considered to correlate to 50% protection [41] and are the current
standard measurement of vaccine efficacy in the field. Immunization with either Ad5- or
Ad6-H2-Con induced equal levels of HI antibodies after a single immunization among
all six viruses tested (Figure 2). Ad5-H2-Con induced protective antibody titers of ≥40
against Korea/68, Singapore/57, and Taiwan/64. Ad6-H2-Con exhibited protective titers
against Singapore/57, Taiwan/64, and Japan/62. There were no statistically significant
differences between the Ad5- and Ad6-H2-Con immunization groups, suggesting that a
single vaccination with either Ad5 or Ad6 will induce equal levels of HI antibody responses.
Next, we assessed protective antibody titers after either a homologous or heterologous boost immunization regimen. A common concern with viral-vectored vaccines is
immune-mediated neutralization of the carrier vector before mounting a significant immune response against the delivered immunogen. In light of this, we evaluated HI titers
against the same panel of human H2 isolates after either a homologous or heterologous
boost vaccination with a serotype switched viral vector carrying the H2 centralized consen-
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sus immunogen (Figure 3). Immunization with Ad5/Ad5-H2-Con and Ad6/Ad6-H2-Con
homologous vaccine strategy induced protective titers of ≥40 against four out of six human
H2 isolates (67% response). In contrast, serotype switching between Ad5/Ad6-H2-Con
and Ad6/Ad5-H2-Con induced an average protective HI titer of ≥40 against five out of
six (83% response) and six out of six (100% response) human H2 isolates, respectively. We
observed a trend of Ad6/Ad5-H2-Con eliciting an average HI titer of ≥40 against 100% of
the strains included in our panel; however, it is worth noting that the differences in HI titer
between the groups against Japan/57 did not reach statistical significance (Figure 3E). Additionally, serotype switching resulted in significantly higher HI antibody titers compared
to homologous prime-boost immunization (Figure 3). These data indicate that serotype
range
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3.2. Adenoviral-Vectored Consensus H2 Immunogen Induces Protective Humoral Immune
Responses
We first evaluated humoral immune responses after a single vaccination with either
Ad5-H2-Con or Ad6-H2-Con and compared the responses to a PBS sham negative control
group. The breadth of antibody responses was assessed using six different human H2 influenza A viruses selected from 1957 to 1968 and assayed by hemagglutination inhibition
(HI) titer. HI titers ≥ 40 are considered to correlate to 50% protection [41] and are the current standard measurement of vaccine efficacy in the field. Immunization with either Ad5-
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3.3. H2 Consensus Provides Protection against Lethal A/Korea/426/1968 Challenge
After completing immune correlate studies, we tested if the H2-Con vaccine is capable of eliciting protection against a divergent lethal H2 influenza infection. BALB/c mice
(n = 10) were infected with 20 times the median lethal dose (20MLD50) of Korea/68 after a
prime-boost vaccination. Mice were vaccinated with homologous or heterologous Ad5/6-
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3.3. H2 Consensus Provides Protection against Lethal A/Korea/426/1968 Challenge
After completing immune correlate studies, we tested if the H2-Con vaccine is capable
of eliciting protection against a divergent lethal H2 influenza infection. BALB/c mice
(n = 10) were infected with 20 times the median lethal dose (20MLD50 ) of Korea/68 after a
prime-boost vaccination. Mice were vaccinated with homologous or heterologous Ad5/6H2-Con or a PBS mock vaccination. Five mice per group were observed for 14 days
post-infection (dpi) to assess differences in morbidity and mortality. We saw complete
protection from lethal H2 challenge in all groups vaccinated with the H2-Con vaccine
regardless of serotype switching (Figure 4). No appreciable differences in weight loss were
observed between any of the adenoviral-vectored H2-Con groups, while mock vaccinated
mice quickly lost weight starting at 3 dpi (Figure 4A). Half of the mice (n = 5) were sacrificed
3 dpi to examine the effect of vaccination on lung viral titers after the challenge. We saw
significantly reduced levels of viral RNA copies present in the lungs in all vaccinated
Vaccines 2022, 10, x FOR PEER REVIEW
9 of 14
groups compared to the PBS negative control group (Figure 4B). All unvaccinated animals
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We first noted that priming with either Ad5 or Ad6 induced similar levels of HI an-
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H1, H3, and H5 influenza strains provides a greater breadth of immunity against divergent
strains than wildtype immunogens in vivo [16,17]. Here we expanded our findings to the
human H2 influenza A virus.
We first noted that priming with either Ad5 or Ad6 induced similar levels of HI
antibody titers, with no statistically significant differences seen between the two vaccine
regimens after one dose, suggesting that a single immunization may provide protective HI
antibody titers regardless of the serotype. We were surprised to see the lowest HI antibody
titers against Japan/57 and RI/57, despite these strains having the highest percent sequence
identity to the H2-Con construct (98.58% and 98.04%, respectively). A closer analysis
of these sequences revealed a shared alanine-to-threonine mutation in both Japan/57
and RI/57 that was not included in the H2-Con construct and is not present in the rest
of our panel of representative divergent strains (Supplemental Figure S1). Importantly,
the positioning of this amino acid substitution is located proximal to antigenic sites B
and D of the H2 hemagglutinin [42–44] and an asparagine residue. It is possible that
these two viruses possess an additional “masking” glycosylation site that would result in
decreased antibody titers measured by HI. Indeed, this mechanism of viral escape was
previously described in the context of two other avian-origin influenza viruses: H7N9 [45]
and H5N1 [46,47]. Although HI titers are a standard correlate of protection, more precise
assays such as ELISAs B cell epitope mapping could help elucidate additional antibodymediated effector functions against these strains. Further studies assessing the implications
of this residue can provide insight into immune escape mechanisms employed by H2
influenza A viruses. Another interesting observation was that priming with Ad6-H2-Con
and boosting with Ad5-H2-Con was able to elicit an average protective antibody titer of
≥40 against 100% of the strains tested. Further, H2-Con provided complete protection
against morbidity and mortality after a challenge with 20 times the median lethal dose of a
divergent human H2 strain. Complete protection against morbidity was likely attributed
to enhanced viral clearance, as mice immunized with H2-Con had significantly reduced
the presence of the virus in the lungs by 3 days post-infection.
A common concern with using an adenoviral-vectored vaccine platform is the neutralization of the vector after repeated immunization. In light of this, we tested the utility
of serotype switching between two species C Ad vectors (Ad5 and Ad6). Both Ad5 and
Ad6 are very well characterized in several strains of mice, with known receptors, tissue
tropism, and immunogenicity. Though Ad5 and Ad6 are both species C adenoviruses, Ad6
exhibits subtle structural differences [48–51], has lower seroprevalence than Ad5 [52], and
can escape preexisting immunity towards Ad5 [53], making it an ideal candidate to be
included in an alternative prime-boosting vaccine strategy. The differences in protective
HI titers seen between priming with either Ad5- or Ad6- before heterologous boosting are
likely due to the increased immunogenicity of Ad6 compared to Ad5. Ad6 was described
to efficiently circumvent Kupffer cell sequestration after systemic delivery [54,55] and has
enhanced hepatocyte transduction during immunization [49,55]. Because Ad6 is able to
efficiently evade this method of sequestration, it is possible this can enhance the protective
responses seen in vivo. It is worth noting that, though we saw enhanced antibody titers
after heterologous boosting, this did not correlate to decreased protection after the challenge, as all groups immunized with the H2-Con had complete protection after Korea/68
infection. This was not unexpected, as all groups exhibited protective antibody titers
against this virus, regardless of heterologous or homologous boosting. In future studies,
we would like to expand our challenge virus panel to incorporate viruses that exhibit
higher sequence divergence than the virus included in our challenge model. However,
the biocontainment practices required for work with infectious human H2 influenza [43]
remain a major hurdle to obtaining viruses that are readily lethal in mouse models and the
expertise required to complete vaccine studies against avian-origin influenza A viruses.
Additionally, given that H2 is still consistently detected in birds, an important contribution
to increasing pandemic preparedness would be creating a consensus construct against
avian H2 influenzas that would provide rapid and broad protection in the event of a
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zoonotic transmission event from birds to humans. This could be complemented by also
exploring alternative Ad vectors. The approval of Ad-vectored vaccines for use against
SARS-CoV-2 has allowed enhanced research of this vaccine modality in recent years, with
substantial improvements to the rate of development, identification of protective immune
correlates, and new recombinant technologies being identified. Importantly, recent research
has begun defining the induction of mucosal immune responses after intranasal administration of recombinant, replication-competent Ad4 expressing a wildtype H5 human
influenza [56]. Clinical translation into humans was marked by durable nasal IgG and
IgA and enhanced levels of circulating H5 HA-specific CD4+ and CD8+ T cells present
in the peripheral blood. Serum neutralizing antibodies could be detected for 26 weeks
after immunization, and adverse effects were mild and correlated with peak viral shedding
at 6 days post-vaccination [57]. Intranasal delivery of a consensus vaccine construct in
a replication-competent Ad vector could offer enhanced mucosal and systemic antibody
responses, as well as cellular-mediated immune responses similar to LAIV vaccines but
with an enhanced safety profile. To the best of our knowledge, no studies have directly
compared the protective efficacy of LAIV versus Ad vectored vaccines and would be an
interesting focal point of a future study.
Furthermore, swine are important reservoirs that have been described to facilitate
efficient reassortment events between multiple strains of the influenza A virus [58,59]. In
2006, H2 influenza was isolated from two independent swine farms [60], highlighting the
potential for these intermediate hosts to enable pandemic strains of H2 to enter human
populations. Because of this, it may be beneficial to produce and administer a broadly
protective avian H2 influenza virus vaccine to these vulnerable populations and, ultimately,
help protect against zoonotic transmission to human populations.
5. Conclusions
In this study, we demonstrated the ability of an adenoviral-vectored H2 centralized consensus immunogen to provide broad protection in vivo. H2 influenza exhibits significant
pandemic potential, and we addressed this concern by creating a broadly cross-protective
vaccine with the ability to protect against a variety of divergent H2 influenza strains. This
strategy of pandemic preparedness has the potential to prevent high rates of mortality in
the event of another pandemic.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/vaccines10060926/s1, Figure S1: Sequence alignment of the
H2 consensus (H2-Con) immunogen, representative strains used in the immunogen design, and
study strains used in immune correlates and challenge; Figure S2: Initial measure of lethality of
representative strains in mouse models.
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